# Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis

> **NCT00913133** · PHASE4 · COMPLETED · sponsor: **Canyon Pharmaceuticals, Inc.** · enrollment: 516 (actual)

## Conditions studied

- Thrombosis

## Interventions

- **DRUG:** Desirudin

## Key facts

- **NCT ID:** NCT00913133
- **Lead sponsor:** Canyon Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 516 (ACTUAL)
- **Last updated:** 2013-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00913133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00913133, "Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00913133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*